Verastem, Inc. (VSTM) Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Verastem, Inc. on June 2, 2025. The filing discloses updated safety and efficacy data from the Phase 1 study of VS-7375 (GFH375), a drug candidate targeting advanced KRAS G12D mutant solid tumors. The data was generated by Verastem's partner, GenFleet Therapeutics, in China and accepted for presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
Key Financial Metrics
This filing is a non-financial disclosure regarding clinical trial progress. The document does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. No financial statements are included in this report.
Material Changes and Clinical Data
The filing reports significant clinical developments regarding the VS-7375 Phase 1 study in China:
- Study Population: 62 patients enrolled receiving oral doses of 100 to 900 mg daily. 98% had metastatic disease, and 75% had received two or more prior lines of therapy.
- Pancreatic Ductal Adenocarcinoma (PDAC): Among 23 efficacy-evaluable patients receiving 400 or 600 mg, the Overall Response Rate (ORR) was 52% and Disease Control Rate (DCR) was 100%.
- Non-Small Cell Lung Cancer (NSCLC): Among 12 efficacy-evaluable patients receiving 400 or 600 mg, the ORR was 42% and DCR was 83%.
- Safety Profile: As of March 31, 2025, no dose-limiting toxicities (DLTs) were observed. Treatment-related adverse events (TRAEs) were mostly Grade 1/2. Common TRAEs (≥20%) included diarrhea, nausea, vomiting, and anemia. Grade 3 TRAEs included decreased neutrophil count (8%) and diarrhea (5%). No TRAE-related deaths were reported.
Guidance, Outlook, and Risks
Future Plans: Verastem plans to conduct a Phase 1/2a study in the U.S. with potential global expansion. The U.S. study will start at a 400 mg dose based on the Chinese data to accelerate progress. The Phase 2a portion will assess efficacy and safety as monotherapy and in combination for pancreatic, colorectal, and non-small cell lung cancers.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Actual results may differ materially due to risks associated with clinical trial timing, regulatory interactions, and the potential for commercialization. The company notes that the U.S. trial is planned but not yet commenced.
Investor Verification Checklist
- Verify the specific patient demographics and prior treatment history in the full press release (Exhibit 99.1).
- Confirm the timeline for the initiation of the U.S. Phase 1/2a study.
- Review the detailed safety data for Grade 3 and higher adverse events in the full clinical report.
- Monitor upcoming investor presentations scheduled for June 2, 2025, for further management commentary.
- Check subsequent filings for any updates on the partnership agreement with GenFleet Therapeutics.